About this Journal Submit a Manuscript Table of Contents

Natural Product Modulators to Overcome Multidrug Resistance in Cancer

Call for Papers

Cancer multidrug resistance is defined as the cross-resistance or insensitivity of cancer cells to the cytostatic or cytotoxic actions of various anticancer drugs which are structurally or functionally unrelated and have different molecular targets. Despite more than three decades of research on the subject, multidrug resistance (MDR) remains one of the major obstacles to successful cancer chemotherapy. Various types of cancers have been observed to exhibit this phenomenon, a strategy that involves cellular and noncellular mechanisms employed by cancer cells to survive the cytotoxic actions of various structurally and functionally unrelated drugs. The emergence of natural products as potential anti-MDR molecules is of particular significance. In fact, compounds from natural products provide one of the most diverse and novel chemical scaffolds suitable for the development of new inhibitors. There is a great chemical diversity that can be utilized, as biologically active components are now extracted from plants, fungi, and even marine organisms then purified and characterized. Most importantly, natural extracts are usually low in toxicity and are well tolerated in the human body. Finally, natural products represent a starting point for the discovery and development of effective MDR modulators, not only for their potential to be used in combination with chemotherapy treatment, but also to rationally design semisynthetic QSAR (quantitative structure-biological activity relationship models) study analogues, with higher potency and fewer pharmacokinetic interactions. Accordingly, there have been significant efforts, but the progress of discovering natural inhibitors is still in the early stages of exploring various extracts/active components.

In the special issue we invite the researchers to contribute original and review articles regarding discovering natural product modulators to overcome multidrug resistance in cancer. Potential topics include, but are not limited to:

  • Discovery of new natural products as modulators of MDR
  • In vitro investigations for anticancer activities of potential modulators
  • Mechanisms of multidrug resistance and reversal of MDR strategies using MDR modulators
  • Animal models for studying the effect of natural products on MDR
  • Preclinical and clinical investigations
  • New cancer therapy by bioactive compounds as MDR modulators
  • SAR studies (structure/activity relationship) of MDR natural compounds
  • Efficacy and safety evaluation of natural products as MDR modulators

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ecam/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ecam/resist/ according to the following timetable:

Manuscript DueFriday, 12 September 2014
First Round of ReviewsFriday, 5 December 2014
Publication DateFriday, 30 January 2015

Lead Guest Editor

Guest Editors

  • Zhe-Sheng Chen, Cancer Pharmacology Laboratory, College of Pharmacy and Health Sciences St. John's University, NY, USA
  • Chung-Pu Wu, Department of Physiology and Pharmacology, Chang Gung University, Tao-Yuan, Taiwan
  • Bharat B. Aggarwal, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA